BioSyent Releases Financial Results for Q2 and H1 2026
Globe Newswire•20/08/2026•17:00 ET
0
Whiz Insights
MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its consolidated financial results for the three months (Q2), six months (H1), and trailing twelve months (TTM) ended June 30, 2026. Key highlights include:
Pharmaceutical Sales11,110,365+14%21,913,472+7%42,325,508+11%
Get started
Create a free account to read the full story.